William Blair Has Pessimistic Outlook of Biogen Q4 Earnings

Biogen Inc. (NASDAQ:BIIB) – Equities research analysts at William Blair dropped their Q4 2024 earnings per share (EPS) estimates for Biogen in a research note issued on Wednesday, October 30th. William Blair analyst M. Minter now anticipates that the biotechnology company will post earnings of $3.33 per share for the quarter, down from their prior estimate of $3.44. The consensus estimate for Biogen’s current full-year earnings is $16.36 per share. William Blair also issued estimates for Biogen’s Q1 2025 earnings at $3.82 EPS, Q2 2025 earnings at $3.79 EPS, Q4 2025 earnings at $3.86 EPS and FY2026 earnings at $14.43 EPS.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 EPS for the quarter, topping the consensus estimate of $3.77 by $0.31. Biogen had a return on equity of 14.98% and a net margin of 16.81%. The company had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.43 billion. During the same quarter in the previous year, the company posted $4.36 earnings per share. The firm’s revenue was down 2.5% compared to the same quarter last year.

A number of other equities research analysts have also recently commented on BIIB. BMO Capital Markets reduced their target price on shares of Biogen from $260.00 to $230.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Wells Fargo & Company reduced their price objective on Biogen from $240.00 to $225.00 and set an “equal weight” rating for the company in a research note on Friday, August 2nd. Raymond James reaffirmed a “market perform” rating on shares of Biogen in a report on Thursday, October 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $292.00 price objective on shares of Biogen in a research report on Monday, September 9th. Finally, Oppenheimer reduced their target price on shares of Biogen from $270.00 to $255.00 and set an “outperform” rating for the company in a research note on Thursday. Ten investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $262.83.

Biogen Stock Performance

Shares of Biogen stock opened at $173.79 on Friday. The stock has a market capitalization of $25.32 billion, a price-to-earnings ratio of 15.70, a PEG ratio of 1.73 and a beta of -0.06. The firm’s fifty day simple moving average is $192.71 and its 200-day simple moving average is $209.47. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 1.48. Biogen has a 12 month low of $173.14 and a 12 month high of $268.30.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 431 shares of Biogen stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $204.22, for a total value of $88,018.82. Following the completion of the sale, the insider now owns 5,316 shares in the company, valued at $1,085,633.52. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by company insiders.

Institutional Trading of Biogen

Institutional investors have recently made changes to their positions in the stock. Arlington Partners LLC boosted its holdings in Biogen by 34.3% in the third quarter. Arlington Partners LLC now owns 19,214 shares of the biotechnology company’s stock valued at $3,724,000 after acquiring an additional 4,902 shares during the last quarter. Duality Advisers LP acquired a new stake in Biogen during the 1st quarter worth approximately $1,290,000. Tocqueville Asset Management L.P. raised its holdings in Biogen by 924.4% in the first quarter. Tocqueville Asset Management L.P. now owns 46,200 shares of the biotechnology company’s stock valued at $9,962,000 after buying an additional 41,690 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Biogen by 0.9% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 386,482 shares of the biotechnology company’s stock valued at $83,337,000 after buying an additional 3,380 shares in the last quarter. Finally, Cetera Investment Advisers raised its stake in shares of Biogen by 235.1% in the 1st quarter. Cetera Investment Advisers now owns 14,860 shares of the biotechnology company’s stock valued at $3,204,000 after acquiring an additional 10,425 shares during the period. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.